"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Coach Mike Shields, a Central Texas coaching veteran and Reicher alum, has died after battling cancer. He led with faith, ...